SAGE THERAPEUTICS INC (SAGE)

US78667J1088 - Common Stock

5.61  +0.61 (+12.2%)

After market: 5.54 -0.07 (-1.25%)

Fundamental Rating

4

SAGE gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SAGE as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, SAGE is valued expensive at the moment.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SAGE has reported negative net income.
In the past year SAGE has reported a negative cash flow from operations.
In the past 5 years SAGE reported 4 times negative net income.
In the past 5 years SAGE reported 4 times negative operating cash flow.

1.2 Ratios

SAGE has a Return On Assets (-54.24%) which is comparable to the rest of the industry.
The Return On Equity of SAGE (-61.18%) is better than 60.35% of its industry peers.
Industry RankSector Rank
ROA -54.24%
ROE -61.18%
ROIC N/A
ROA(3y)-41.91%
ROA(5y)-32.08%
ROE(3y)-45.58%
ROE(5y)-35.9%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

SAGE has a Gross Margin of 91.75%. This is amongst the best in the industry. SAGE outperforms 93.81% of its industry peers.
In the last couple of years the Gross Margin of SAGE has remained more or less at the same level.
SAGE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.82%
GM growth 5YN/A

More info and screens

7

2. Health

2.1 Basic Checks

SAGE does not have a ROIC to compare to the WACC, probably because it is not profitable.
SAGE has more shares outstanding than it did 1 year ago.
SAGE has more shares outstanding than it did 5 years ago.
There is no outstanding debt for SAGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -4.62, we must say that SAGE is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SAGE (-4.62) is worse than 60.00% of its industry peers.
There is no outstanding debt for SAGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.62
ROIC/WACCN/A
WACC11.91%

2.3 Liquidity

SAGE has a Current Ratio of 10.02. This indicates that SAGE is financially healthy and has no problem in meeting its short term obligations.
SAGE's Current ratio of 10.02 is amongst the best of the industry. SAGE outperforms 80.71% of its industry peers.
A Quick Ratio of 10.02 indicates that SAGE has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 10.02, SAGE belongs to the best of the industry, outperforming 81.06% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.02
Quick Ratio 10.02

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 37.80% over the past year.
Looking at the last year, SAGE shows a very strong growth in Revenue. The Revenue has grown by 833.32%.
Measured over the past years, SAGE shows a decrease in Revenue. The Revenue has been decreasing by -0.87% on average per year.
EPS 1Y (TTM)37.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.6%
Revenue 1Y (TTM)833.32%
Revenue growth 3Y-57.35%
Revenue growth 5Y-0.87%
Sales Q2Q%337.08%

3.2 Future

The Earnings Per Share is expected to grow by 14.20% on average over the next years. This is quite good.
Based on estimates for the next years, SAGE will show a very strong growth in Revenue. The Revenue will grow by 32.59% on average per year.
EPS Next Y34.98%
EPS Next 2Y26.83%
EPS Next 3Y19.62%
EPS Next 5Y14.2%
Revenue Next Year-39.08%
Revenue Next 2Y16.5%
Revenue Next 3Y31.53%
Revenue Next 5Y32.59%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SAGE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SAGE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as SAGE's earnings are expected to grow with 19.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.83%
EPS Next 3Y19.62%

More info and screens

0

5. Dividend

5.1 Amount

SAGE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAGE THERAPEUTICS INC

NASDAQ:SAGE (12/20/2024, 8:00:01 PM)

After market: 5.54 -0.07 (-1.25%)

5.61

+0.61 (+12.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29 2024-10-29/amc
Earnings (Next)02-12 2025-02-12/amc
Inst Owners89.88%
Inst Owner Change-2.13%
Ins Owners0.59%
Ins Owner Change2.38%
Market Cap343.16M
Analysts66.15
Price Target9.6 (71.12%)
Short Float %12.11%
Short Ratio7.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.85%
Min EPS beat(2)-0.48%
Max EPS beat(2)2.18%
EPS beat(4)1
Avg EPS beat(4)-10.9%
Min EPS beat(4)-38.16%
Max EPS beat(4)2.18%
EPS beat(8)2
Avg EPS beat(8)-8.19%
EPS beat(12)5
Avg EPS beat(12)-5.04%
EPS beat(16)7
Avg EPS beat(16)318.47%
Revenue beat(2)1
Avg Revenue beat(2)1.82%
Min Revenue beat(2)-4.11%
Max Revenue beat(2)7.74%
Revenue beat(4)3
Avg Revenue beat(4)15.78%
Min Revenue beat(4)-4.11%
Max Revenue beat(4)34.14%
Revenue beat(8)5
Avg Revenue beat(8)10.5%
Revenue beat(12)6
Avg Revenue beat(12)-0.21%
Revenue beat(16)7
Avg Revenue beat(16)111.82%
PT rev (1m)-29.82%
PT rev (3m)-35.48%
EPS NQ rev (1m)-1.13%
EPS NQ rev (3m)-1.09%
EPS NY rev (1m)-0.6%
EPS NY rev (3m)-0.61%
Revenue NQ rev (1m)0.35%
Revenue NQ rev (3m)0.57%
Revenue NY rev (1m)-0.16%
Revenue NY rev (3m)8.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.23
P/FCF N/A
P/OCF N/A
P/B 0.62
P/tB 0.62
EV/EBITDA N/A
EPS(TTM)-6.83
EYN/A
EPS(NY)-4.03
Fwd EYN/A
FCF(TTM)-5.23
FCFYN/A
OCF(TTM)-5.23
OCFYN/A
SpS1.74
BVpS9.02
TBVpS9.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.24%
ROE -61.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.75%
FCFM N/A
ROA(3y)-41.91%
ROA(5y)-32.08%
ROE(3y)-45.58%
ROE(5y)-35.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.82%
GM growth 5YN/A
F-Score6
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.35%
Cap/Sales 0.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.02
Quick Ratio 10.02
Altman-Z -4.62
F-Score6
WACC11.91%
ROIC/WACCN/A
Cap/Depr(3y)43.68%
Cap/Depr(5y)78.95%
Cap/Sales(3y)6.23%
Cap/Sales(5y)20.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.6%
EPS Next Y34.98%
EPS Next 2Y26.83%
EPS Next 3Y19.62%
EPS Next 5Y14.2%
Revenue 1Y (TTM)833.32%
Revenue growth 3Y-57.35%
Revenue growth 5Y-0.87%
Sales Q2Q%337.08%
Revenue Next Year-39.08%
Revenue Next 2Y16.5%
Revenue Next 3Y31.53%
Revenue Next 5Y32.59%
EBIT growth 1Y43.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.17%
EBIT Next 3Y18.72%
EBIT Next 5Y13.65%
FCF growth 1Y25.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.66%
OCF growth 3YN/A
OCF growth 5YN/A